|
沙发
楼主 |
发表于 2015-8-2 22:41:59
|
只看该作者
Rojjer 回复:
已经获得批准:“On Sept. 15, 2009, MedImmune received approval from the U.S. Food and Drug Administration (FDA) for its live attenuated influenza vaccine (LAIV) against the novel H1N1 influenza virus. The vaccine is indicated for the active immunization of individuals 2-49 years of age against influenza caused by pandemic (H1N1) 2009 virus. ”
今天看邮件的时候也看到了MedImmune公司的关于H1N1 LAIV的论文:
J. Virol. doi:10.1128/JVI.02106-09
Copyright (c) 2009, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
Generation of live attenuated novel influenza A/California/7/09 (H1N1) vaccines with high yield in embryonated chicken eggs
Zhongying Chen, Weijia Wang, Helen Zhou, Amorsolo L. Suguitan Jr., Cindy Shambaugh, Lomi Kim, Jackie Zhao, George Kemble, and Hong Jin*
MedImmune, 319 North Bernardo Ave, Mountain View, CA 94043
* To whom correspondence should be addressed. Email: jinh@medimmune.com. http://jvi.asm.org/cgi/content/a ... cetype=HWCIT&ct |
|